Chinese-based Sinovac Biotech has released mixed findings from its two first clinical trials for a COVID-19 vaccine. Though the early clinical trials indicate that the vaccine is well-tolerated, the company has reported that it generates lower levels of protective antibodies in the bloodstream, compared with levels found in patients who have recovered from the coronavirus. Sinovac believes its vaccine will still be effective despite the lower antibody levels, and phase III trials are currently being conducted in Indonesia, Brazil, and Turkey. Yourway has 21 strategically located global depots worldwide, including São Paulo, Tel Aviv, and Singapore, to ensure that clinical trial supplies are transported smoothly from one location to another — no matter where trials take place.